RxDoctor Payments Data

Tyler Provost, DO

Family Medicine · Thomson, GANPI 1588186191

Payments from drug & device makers

$2,421in general payments, 2019–2025

Across 117 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$372
  • AstraZeneca$335
  • AbbVie$235
  • Bayer$214
  • Radius Health, Inc.$188
  • Lilly USA, LLC$125
  • plus $952 from 22 others

What the payments were for

  • Food & beverage$2,421100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,421 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$10,417
Medicare patients
120
Services billed
828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$70,729
EliquisApixaban55$44,884
JardianceEmpagliflozin33$40,532
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$24,593
JanuviaSitagliptin Phosphate16$18,095
MyrbetriqMirabegron16$17,955
Janumet XrSitagliptin Phos/Metformin Hcl15$13,053
Advair HfaFluticasone Propion/Salmeterol18$6,153
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,420
ZubsolvBuprenorphine Hcl/Naloxone Hcl11$4,866
LantusInsulin Glargine,hum.Rec.Anlog11$3,892
SymbicortBudesonide/Formoterol Fumarate15$3,151
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,717
Potassium Chloride24$2,679
Albuterol Sulfate HfaAlbuterol Sulfate90$2,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$98$70,72965 claims
PfizerEliquis$83$44,88455 claims
Boehringer IngelheimJardiance$74$40,53233 claims
GSKTrelegy Ellipta$112$24,59334 claims
Sanofi-aventis U.S. LLCLantus$94$3,89211 claims
AstraZenecaSymbicort$335$3,15115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Thomson

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →